Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSPPC-96 + Bevacizumab in Recurrent GBM
NCT01814813Phase 2Terminated
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jun 2013
- Primary completion
- Apr 2017
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of vitespen in glioblastoma (GBM), Gliosarcoma (GS), sponsored by Cancer and Leukemia Group B. Started Jun 2013; status: terminated.
02
Drugs
vitespen
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT01814813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01814813.